FDA approval news will change the game .. It is anticipated that a 510(k) application will be filed with the FDA in approximately 90 days. Assuming no extended delays in FDA review, approval of Altrazeal® exSALT(TM) could occur as early as the third quarter of 2011. The antimicrobial segment of the North American advanced wound care market is projected to grow in the next 5 years to be in excess of $750 million with annual growth rates above 15%.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.